| INTRODUCTION
Multifocal motor neuropathy (MMN) is an immune-mediated peripheral neuropathy, characterized by progressive asymmetric distal muscle weakness predominantly in the upper extremities, and pure motor involvement.
1,2 Current therapeutic options for MMN are limited, and intravenous immunoglobulin (IVIg) therapy is only one established treatment; as MMN patients do not respond to corticosteroids or plasma exchange. 3, 4 So far, 5 randomized, placebo-controlled trials of IVIg for MMN have shown significant short-term improvement in muscle strength, up to 12 weeks. [5] [6] [7] [8] [9] Based on these data, the joint European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) taskforce recommended IVIg (2 g/kg) as a first-line treatment for MMN. 1 The taskforce also proposed that "if this induction therapy is effective, repeated IVIg should be considered with the frequency of maintenance therapy dose are 1 g/kg every 2-4 weeks, or 2 g/kg every 1-2 months". However, there is limited evidence for the dose and interval of maintenance IVIg.
No long-term clinical trials that investigated the efficacy and safety of IVIg in MMN have been performed. Four retrospective studies have described MMN patients who have received repeated IVIg therapy over several years, and suggested that it may be used as the long-term treatment option for MMN. [10] [11] [12] [13] In these reports, the IVIg regimen, interval, and treatment response varied among patients; some experienced sustained remission and others had gradual progression of muscle weakness presumably because of Wallerian degeneration. The aim of this clinical trial is to study the efficacy and safety of maintenance IVIg (1.0 g/kg every 3 weeks) for 52 weeks in patients with MMN.
| MATERIALS AND METHODS

| Study design and patients
This study was a multi-center, single-arm open phase 3 trial conducted at 11 Japanese tertiary hospitals. The study procedures were in accordance with the Declaration of Helsinki, and Japanese Good 
| Procedures
The study design and trial profile are shown in Figure For neurological assessment, MRC sum score, hand-grip strength, and Guy's Neurological Disability Scale (GNDS) score 15 were assessed at each visit. Each neurological assessment, except at week 52, was conducted before administration of IVIg.
FIGURE 1 Study design and trial profile
| Outcome measures
The outcome measures were MRC sum score, hand-grip strength score, and GNDS score. Difference in the mean scores at week 1 and week 52 was calculated. These measures were not distinguished as primary and secondary because the number of MMN patients included in this trial was small. Safety assessments included any adverse event during the study period.
| Data analyses
Analyses were performed by the full analysis set which included all patients who received the drug at least once. Missing data of MRC sum score, hand-grip strength, and GNDS score were input by data at the last visit (the last observation carried forward method). Confidence interval (CI) was calculated using the Clopper-Pearson exact method for both periods. The target number of 10 patients was set in view of the rarity of MMN. All analyses were performed with the statistical software package SAS, release 9.2 (SAS Institute Inc., Cary, North Carolina). Statistical comparison was not performed because of the small number of patients included.
3 | RESULTS
| Patient disposition
The study was conducted from June 2013, and ended in June 2015. A total of 15 patients were screened. Two patients were ineligible, and the remaining 13 were enrolled ( Figure 1) ; 12 of them were responders to prior IVIg treatment (2.0 g/kg), and the remaining 1 was treatment-naïve. During the study, 2 patients discontinued the study because of an adverse event (dysphagia) and decision of the investigator (slight decline of muscle strength), respectively. Of the 13 patients, 11 completed the 52-week study. IVIg treatment before the study. The mean baseline serum IgG level was 1296 mg/dL (normal range, 900-1800 mg/dL).
| Efficacy
Results of the outcome measures are shown in Table 2 . The mean value of MRC sum score, hand-grip strength, and GNDS score 
| Safety
A total of 12 (92.3%) of the 13 patients experienced adverse events (95% CI: 64.0%-99.8%). Table 3 shows details of adverse events with the incidence of 15% or more. Frequent events were nasopharyngitis (38.5%), headache (23.1%), and contusion (23.1%). Additionally, adverse drug reactions were observed in 69.2% (9/13 patients, 95%
CI, 38.6%-90.9%). No death occurred during the study.
Three patients experienced serious adverse events, including coronary artery stenosis (n = 1), dysphagia (n = 1), and inguinal hernia (n = 1). None of them was considered to relate with IVIg. The regimen used in this trial can be an option to achieve sustained remission in MMN at least for 52 weeks.
In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), approximately 25% of patients have long-lasting remission without immunological treatment, 16, 17 and prolonged maintenance therapy could be over treatment. However, such remitting course is rare for MMN, 10 and MMN patients may require maintenance therapy for more than 52 weeks. Therefore the duration of IVIg therapy, as well as, the optimal regimen, for longer maintenance IVIg for MMN patients should be evaluated in future studies.
A recent clinical trial for CIDP using the same maintenance dose (1.0 g/kg) and interval (every 3 weeks) for 52 weeks has also shown similar long-term efficacy. 18 In that study, 2 of the 49 enrolled elderly patients with hypertension or diabetes developed cerebral infarction.
Whereas thromboembolic events did not occur in the present study, hyperviscosity-induced thrombotic complications should be carefully monitored during a long-term IVIg treatment.
In conclusion, 52-week maintenance IVIg therapy appears to be safe and efficacious to prevent a relapse for MMN patients. The 
